Journals / Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2019 / Cilt: 52 - Sayı: 2

Serologic Indicators of HBV, HCV and HIV in Hemodialysis Patients in Van Training and Research Hospital

Van Eğitim ve Araştırma Hastanesindeki Hemodiyaliz hastalarında HBV, HCV ve HİV serolojik İndikatörleri

Pages
153–157
Publication Date
2019-07-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Appropriate infection control measures, immunizations and education of patients and health workers come to the forefront in reducing the frequency of blood-borne infections in hemodialysis patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: It was aimed to examine the blood-borne infections in patients to whom hemodialysis is applied due to chronic renal failure and evaluating the effectiveness of infection control programs in this study.Materials and methods: Patients who underwent routine hemodialysis between January and August 2018 were included into the study.
📊
Key Findings & Data:It was detected that Anti-HCV reactive patients underwent dialysis for more than five years and they had a lower mean age (p<0,005).
💡
Conclusion & Impact:Conclusion: Appropriate infection control measures, immunizations and education of patients and health workers come to the forefront in reducing the frequency of blood-borne infections in hemodialysis patients.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Hemodiyaliz · Hepatit B virüs · Hepatit C virüs

Abstract

Objectives: It was aimed to examine the blood-borne infections in patients to whom hemodialysis is applied due to chronic renal failure and evaluating the effectiveness of infection control programs in this study.Materials and methods: Patients who underwent routine hemodialysis between January and August 2018 were included into the study. The study was designed as a retrospective. The blood samples taken from patients during their health screenings were tested with the macro ELISA method for HBsAg, Anti-HBs, Anti-HCV and Anti-HIV observations at the microbiology laboratory and the clinical information was acquired from patient files.Results: There were no patients who developed reactivity of chronic HBsAg and anti-HIV based on dialysis. One of eight Anti-HCV reactive patients was not included in the analyses since the patient had the disease before undergoing dialysis. It was detected that Anti-HCV reactive patients underwent dialysis for more than five years and they had a lower mean age (p<0,005). In only five (55.5%) of nine patients who received hepatitis B vaccine, protective antibody titer was reached. Conclusion: Appropriate infection control measures, immunizations and education of patients and health workers come to the forefront in reducing the frequency of blood-borne infections in hemodialysis patients.

Özet

AMAÇ: Bu çalışmada, kronik böbrek yetmezliği tanısıyla hemodiyaliz uygulanan hastalarda; kan yoluyla bulaşan enfeksiyonlar incelenerek enfeksiyon kontrol programlarının etkinliğinin değerlendirilmesi amaçlanmıştır. GEREÇ ve YÖNTEM: Çalışmada 1 Ocak- 1 Ağustos 2018 tarihleri arasında rutin hemodiyaliz uygulanan hastaların dosyaları restrospektif olarak incelendi. Hastaların demografik özellikleri ve hastanemiz mikrobiyoloji laboratuvarında macro ELİSA yöntemi ile çalışılan HBsAg, Anti-HBs, Anti-HCV ve Anti-HİV serolojileri kaydedildi. BULGULAR: Hemodiyaliz sonrası HBsAg ve Anti-HİV reaktifliği gelişen hasta bulunmamakta olup; Anti-HCV reaktifliği olan yedi hasta saptandı. Anti-HCV reaktif hastaların beş yıldan daha uzun diyalize girdiği ve yaş ortalamalarının daha düşük olduğu saptandı (p<0,005). Hepatit B aşısı yapılan dokuz hastanın yalnızca beşinde (%55,5) koruyucu antikor titresine ulaşıldığı görüldü. SONUÇ: Hemodiyaliz hastalarında kan yoluyla bulaşan enfeksiyonların sıklığını azaltmada uygun enfeksiyon kontrol önlemleri, hasta ve sağlık çalışanlarının bağışıklaması ve eğitimleri ön plana çıkmaktadır.

🔖

Cite This Article

SAYAR, M. S., BULUT, D., SOLAY, A. H. (2019). Serologic Indicators of HBV, HCV and HIV in Hemodialysis Patients in Van Training and Research Hospital. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 52 - Sayı: 2, 153–157. https://ajindex.com/articles/712740

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bernieh B. Viral hepatitis in hemodialysis: An update. J. Transl. Intern. Med. 2015;3:93-105. DOI: 10.1515/jtim-2015-0018
  2. Yadegarynia D, Hatamai H, Roodsari SR, Arab-mazar Z. Seroprevalence of hepatitis B, C and D viral among hemodialysis patients in Tehran. 2017;9:195–199. PMCID: PMC5719514
  3. Temiz H, Kaya Ş, Berekatoğlu N, Temiz S, Danış R. Hemodiyaliz Hastalarında HBV, HCV ve HIV Seroprevalansı ve Hepatit B Aşılaması ile Oluşan Antikor Cevabının Değerlendirilmesi. Viral Hepatit Derg. 2013;19:140–143. Doi: 10.4274/Vhd.66375
  4. Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK. Hepatitis C in hemodialysis patients. World J. Hepatol. 2015;7:548–558. DOI: 10.4254/wjh.v7.i3.548
  5. Tozun N, Ozdoğan O, Cakaloglu Y et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21: 1020–1026. DOI:
  6. World Health Organization (WHO). http://apps.who.int/gho/data/view.main.22100WHO?lang=en. Erişim tarihi: 18.12.2018
  7. Mahboobi N, Porter SR, Karayiannis P, Alavian S. Dental Treatment as a Risk Factor for Hepatitis B and C Viral Infection. A Review of the Recent Literature.J Gastrointestin Liver Dis.2013; 22:79–86. PMID:23539395
  8. Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World J. Gastroenterol.2017;23:151–166. DOI: 10.3748/wjg.v23.i1.151
  9. İdilman R, Baykam N, Kaymakoğlu S et al. Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus. Turk J Gastroenterol. 2017;28:90–93. DOI: 10.5152/tjg.2017.21
  10. Kaplan Ö, Bakıcı MZ, Çelik C, Kayataş M, Candan F. Cumhuriyet Üniversitesi Araştırma ve Uygulama Hastanesi Hemodiyaliz Ünitesi Hastalarının HBsAg ve Anti HCV Seropozitiflikleri. Viral Hepatit Derg. 2013;19(3):126–130. Doi: 10.4274/Vhd.88597
  11. Tozun N, Ozdogan O, Cakaloğlu Y et al. Seroprevalance of hepatitis B and C infections in Turkey. Turkish J. Gastroenterol. 2017;28:147–148. DOI: 10.5152/tjg.2017.1710021
  12. World Health Organization. Global Hepatitis Report 2017. 2017;(83):1-83
  13. Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J. Hepatol. 2015;7:885–895. doi: 10.4254/wjh.v7.i6.885
  14. Luma HN, Halle MP, Bagnaka Eloumou SAF et al. Seroprevalence of human immunodefi